Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.
WASHINGTON, Dec. 16, 2025 /PRNewswire/ -- Today, the U.S. Department of Health and Human Services (HHS) officially added Duchenne muscular dystrophy (Duchenne) to the Recommended Uniform Screening ...
CHARLESTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company” or "Solid”), a life sciences company developing precision genetic medicines for neuromuscular ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...
PHOENIX — Jace Taylor is a rambunctious 4-year-old boy. He runs, jumps and plays with his friends. He isn’t aware that genetically, he’s different from other children. “I think he’s too young to ...
GlobalData on MSN
Santhera grants Agamree rights to Nxera for DMD
Santhera Pharmaceuticals has entered into an exclusive licensing agreement with Nxera Pharma for Agamree to treat DMD in ...
Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon approval SEATTLE, Dec. 11, 2025 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback